Annual report pursuant to Section 13 and 15(d)

Collaborative Arrangements (Details)

v3.19.3.a.u2
Collaborative Arrangements (Details) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Dec. 31, 2019
May 31, 2019
Apr. 30, 2018
Oct. 31, 2017
Mar. 31, 2017
Dec. 31, 2015
Feb. 29, 2012
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Sep. 30, 2018
Apr. 30, 2017
Aug. 31, 2015
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Liability, revenue recognized                 $ 68,458,000 $ 60,594,000        
Contract with customer, liability $ 2,044,000             $ 8,288,000 2,044,000 8,288,000 $ 18,966,000      
GSK Platform                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Liability, revenue recognized                 2,000,000.0          
Contract with customer, liability 0             0 0 0        
Merck | Technology Transfer and License Agreement                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Contingent receivable                           $ 15,000,000.0
Liability, revenue recognized                 4,000,000.0 4,100,000 4,100,000      
Contract with customer, liability 0             0 0 0        
Merck | Technology Transfer and License Agreement | Maintenance [Member]                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Liability, revenue recognized                 900,000          
Merck | Supply Agreement                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Liability, revenue recognized                 0 1,300,000 1,300,000      
Term of collaborative research and development agreement             5 years              
Term of agreement extension           5 years                
Merck | Supply Agreement | Product Sales                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Liability, revenue recognized                 15,100,000 12,300,000 9,000,000.0      
Tate & Lyle | Supply Agreement                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Contract with customer, liability 2,000,000.0             2,000,000.0 2,000,000.0 2,000,000.0        
Tate & Lyle | Research and Development Agreement                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Liability, revenue recognized                 100,000 7,100,000 3,200,000      
Contract with customer, liability 0             0 0 0     $ 3,000,000.0  
Term of collaborative research and development agreement         21 months                  
Nestec Ltd. (Nestle Health Sciences) | Global Development, Option and License Agreement                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Liability, revenue recognized                 1,900,000 9,900,000 7,200,000      
Contract with customer, liability 13,000     $ 14,000,000.0       1,900,000 13,000 1,900,000        
Nestec Ltd. (Nestle Health Sciences) | Global Development, Option and License Agreement | Sales-based Milestone                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Target sales for sales milestone       1,000,000,000.0                    
Nestec Ltd. (Nestle Health Sciences) | Global Development, Option and License Agreement | Milestone One                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Contract with customer, liability       4,000,000.0                    
Nestec Ltd. (Nestle Health Sciences) | Global Development, Option and License Agreement | Milestone Two                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Contract with customer, liability       1,000,000.0                    
Nestec Ltd. (Nestle Health Sciences) | CDX-6114                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Cumulative catch-up adjustment to revenue                 3,000,000.0          
Nestec Ltd. (Nestle Health Sciences) | Strategic Collaboration Agreement                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Liability, revenue recognized                 5,400,000 3,600,000 500,000      
Contract with customer, liability 0             800,000 0 800,000 $ 1,200,000 $ 600,000    
Porton                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Liability, revenue recognized               2,800,000            
Contract with customer, liability 0             $ 0 0 $ 0        
Porton | Milestone One                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Contract with customer, liability     $ 500,000                      
Number of days for payment     30 days                      
Porton | Milestone Two                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Contingent receivable     $ 1,500,000                      
Novartis                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Liability, revenue recognized                 11,300,000          
Contract with customer, liability 0 $ 5,000,000.0             0          
Term of collaborative research and development agreement   20 months                        
Novartis | Computer equipment and software                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Contingent annual receivable increase   $ 8,000,000.0                        
Novartis | Milestone One                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Contingent receivable   4,000,000.0                        
Novartis | Milestone Two                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Contingent receivable   $ 5,000,000.0                        
Novartis | Revenue sharing arrangement                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Term of collaborative research and development agreement   20 months                        
Roche | Milestone One                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Contract with customer, liability $ 750,000               750,000          
Number of days for payment 45 days                          
Roche | Milestone Two                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Contingent receivable $ 850,000               850,000          
Number of days for payment 60 days                          
Minimum | GSK Platform                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Contingent receivable $ 5,750,000               5,750,000          
Maximum | GSK Platform                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Contingent receivable $ 38,500,000               $ 38,500,000          
Maximum | Nestec Ltd. (Nestle Health Sciences) | Global Development, Option and License Agreement | Research and Development Agreement                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Contingent receivable       85,000,000.0                    
Maximum | Nestec Ltd. (Nestle Health Sciences) | Global Development, Option and License Agreement | Sales-based Milestone                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Contingent receivable       $ 250,000,000.0